Cognition Therapeutics, Inc. (CGTX)
$1.94
Rating:
Recommendation:
-
| Symbol | CGTX |
|---|---|
| Price | $1.94 |
| Beta | 0.000 |
| Volume Avg. | 0.08M |
| Market Cap | 56.769M |
| Shares () | - |
| 52 Week Range | 1.07-6.269 |
| 1y Target Est | - |
| DCF Unlevered | CGTX DCF -> | |
|---|---|---|
| DCF Levered | CGTX LDCF -> | |
| ROE | -71.98% | Strong Sell |
| ROA | -61.45% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 25.28% | Neutral |
| P/E | -1.96 | Sell |
| P/B | 1.14 | Strong Buy |
Latest CGTX news
About
Download (Excel)Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.